Circadian fluctuations of melatonin, tumor necrosis factor-α and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer

Journal of Experimental and Clinical Cancer Research

Volumn 22, Issue 2, 2003, Pages 171-178

  Muc Wierzgon, Malgorzata ^a   Nowakowska Zajdel, E ^a   Zubelewicz, B ^a   Wierzgon, J ^b   Kokot, T ^a   Klakla, K ^a   Szkilnik, R ^a   Wiczkowski, A ^c  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c Silesian Medical University ^*

Author keywords

Cancer; Melatonin; Soluble receptors; Tumor Necrosis Factor

Indexed keywords

MELATONIN; PROTEIN P55; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOREGULATION; BLOOD LEVEL; BLOOD SAMPLING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, CD; CIRCADIAN RHYTHM; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MELATONIN; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOIMMUNOASSAY; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; STOMACH NEOPLASMS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038037959     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Blalock J.E.: The syntax of immune-neuroendocrine communication. Immunol. Today 15: 504-508, 1994.
2. Butler L.D., Layman P.E., Riedl R.L.: Neuroendocrine regulations of in vivo cytokine production and effects. In vivo regulatory networks involving the neuroendocrine system, interleukin-1, TNF. J. Neuroimmunol. 24: 143-148, 1989.
3. Braczkowski R., Zubelewicz B., Romanowski W., Lissoni P., Barni S.: Modulation of Tumor Necrosis a toxicity by the pineal hormone Melatonin in metastatic solid tumor patients. Ann. N.Y.Ac. Sci. 768:334-336, 1995.
4. Maestroni G.J.M.: Mini-review: The immunoneuroendocrine role of melatonin. J. Pineal Res. 14: 1-10, 1993.
5. Mucha S., Zylinska K., Zerek-Melen G.: Effect of Interleukin-1 on in vivo melatonin secretion by the pineal gland in rats. Adv. Pineal Res. 7: 177-182, 1993.
6. Viviani S., Bidoli P., Spinazze S., Rovelli F., Lissoni P.: Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of IL-2 in advanced small cell lung cancer patients. J. Pineal Res. 12: 114-117, 1992.
7. Aggarwal B.B., Natarajan K.: Tumor necrosis factors: Developments during the last decade Eur. Cytokine Netw. 7: 93-125, 1996.
8. Osawa T., Bonavida T.: Mollecular and cellular biology and clinical relevance of Tumor Necrosis Factor. W. Fiers and WA Buurmann (eds) Karger, Basel. 1992:25.
9. Erikstein B.K., Smeland E.B., Blomhoff H.K. et al.: Independent regulation of 55-kDa and 75 kDa tumor necrosis factor receptors during activation of human peripheral blood b lymphocytes. Eur. J. Immunol. 21: 1033-1038, 1991.
10. Gatanaga T., Granger G.A.: Basic and clinical studies of soluble tumor necrosis factor/lymphotoxin receptors. In: Tumor Necrosis Factor: molecular and cellular biology and clinical relevance. W. Fiers and WA Buurmann (eds) Basel, Karger. 1992:187.
11. Neylor M.S., Stamp G.W., Foulkes W.D. et al.: Tumor necrosis factor and its receptors in disease progression. J. Clin. Invest. 91: 2194-2206, 1993.
12. Aderka D., Engelmann H., Hornik V. et al.: Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 51: 5602-5607, 1991.
13. Muc-Wierzgon M., Madej K., Baranowski M., Wierzgon J.: Circadian rhythmometry of serum endogenous tumor necrosis factor alpha in patients with colorectal cancer metastases. Eur Cytokine Netw. 9: 193-196, 1998.
14. Muc-Wierzgon M., Madej K., Baranowski M.: Is there correlation between Tumor Necrosis Factor α and soluble p-55 receptor plasma levels in advanced gastointestinal cancer patients? J. Biol. Regul. Homeost. Agents 10: 95-96, 1997.
15. Lissoni P., Barni S., Tancini G. et al.: Role of the pineal gland in the control of macrophage functions and its possible implication in cancer. J. Biol. Reg. Homeost. Ag. 8:126-129, 1995.
16. Touitou Y., Haus E.: Biologic rhythm in clinical and laboratory medicine. Springer-Verlag Berlin, Heidelberg, New York. 1994.65.
17. Maestroni G.J.M.: The immunoendocrine role of melatonin. J. Pineal. Res. 14:1-10, 1993.
18. Muc-Wierzgon M., Madej K., Baranowski M.: Fluctuation of endogenous TNF concentration in plasma in advanced cancer patients. J Biol. Regul. Homeost. Agents 10:25-26, 1996.
19. Muc-Wierzgon M., Madej K., Baranowski M.: Diurnal rhythmicity of endogenous TNF concentration in plasma of advanced gastrointestinal cancer patients. Oncol. Rep.4: 637-640, 1994.
20. Lissoni P., Viviani S., Bajetta E.: A clinical study of the pineal gland activity in oncologic patients. Cancer 57: 837-842, 1986.
21. Lissoni P., Barni S., Crispino S. et al.: Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur. J. Cancer Clin. Oncol. 25: 789-795, 1989.
22. Regelson W., Pierpaoli W.: Melatonin a rediscovered antitumor hormone? Cancer Invest. 5: 379-385, 1987.
23. Liebmann P., Reibnegger G., Lehofer M. et al.: Circadian rhythm of the soluble p-75 TNF receptor in humans: a possible explanation for the circadian kinetics of TNFα effects. Neuroimm. 5: 29, 1998